News Astellas GLOWing as Claudin drug aces gastric cancer trial Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.
News Merck suffers a setback in its TIGIT programme Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
News Servier’s $1.8bn Agios deal delivers glioma prospect IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.
News Exscientia builds cancer pipeline with two BMS drugs LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
News Rumour of Pfizer, Seagen deal is true, with $43bn price tag Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.
News Rezzayo antifungal okayed as Candida auris rings alarm bells Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
